Aerie Pharmaceuticals Incのショートレシオ
Aerie Pharmaceuticals Incのショートレシオは何ですか。
Aerie Pharmaceuticals Incのショートレシオは1.53です。
ショートレシオの定義は何ですか。
短期比率は、 短期売却株式数を日々の平均金額で割ったものです。
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
NASDAQのセクタHealth Careにおけるショートレシオの企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似のショートレシオ
- Franchise Global Health Incのショートレシオは1.52です。
- Progressiveのショートレシオは1.52です。
- 94383のショートレシオは1.52です。
- Lument Finance Trustのショートレシオは1.52です。
- Cohen & Steers Select Preferred and Income Fund Incのショートレシオは1.52です。
- Everspin Technologies Incのショートレシオは1.52です。
- Aerie Pharmaceuticals Incのショートレシオは1.53です。
- Celanese Corpのショートレシオは1.54です。
- Marvell Technology Incのショートレシオは1.54です。
- Evrim Resourcesのショートレシオは1.54です。
- Steppe Goldのショートレシオは1.54です。
- Intelのショートレシオは1.54です。
- Sanofiのショートレシオは1.54です。